Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Presented By
Dr Xiaowen Tang; Dr James Foran
Conference
ASH 2019
Trial
Phase 2, ECOG-ACRIN E2906
Two presentations by Dr Xiaowen Tang (Soochow University, China) and Dr James Foran (Mayo Clinic, Jacksonville, USA) suggested that decitabine maintenance therapy is an effective and safe treatment option to prevent relapse after transplantation for high-risk acute myeloid leukaemia (AML) patients [1,2]. Relapse is the most common cause of treatment failure following intensive induction and consolidation therapy in older adults with AML. The prospective, randomised, multicentre, phase 2 ECOG-ACRIN E2906 trial investigated patient outcomes after decitabine maintenance therapy compared with observation in intensively-treated older patients (≥60 years) with AML. Feasibility of decitabine maintenance was previously confirmed in a large phase 2 study [3]. The primary clinical results from the E2906 trial (n=727) demonstrated inferior overall survival of the singl...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on